Ear, Nose and Throat Department, Guys and St. Thomas' Hospital , London, United Kingdom.
Laryngoscope. 2009 Dec;119(12):2459-65. doi: 10.1002/lary.20653.
OBJECTIVES/HYPOTHESIS: We present a large, prospective cohort study following patients who underwent surgery for chronic rhinosinusitis (CRS), with or without nasal polyps, in hospitals in England and Wales. Five-year outcomes will be reported, and we will revisit a previous analysis of the effectiveness of extensive surgery in the treatment of nasal polyposis.
Baseline clinical data was collected for 3,128 patients undergoing surgery for CRS (with or without nasal polyps). Outcomes are described in terms of the proportion of patients undergoing revision surgery and mean Sino-Nasal Outcome Test (SNOT-22) scores.
A total of 1,459 (52.2%) patients responded to 5-year follow-up. Revision surgery rates increased at each time point. Of the patients responding, 279 patients (19.1%) had undergone further surgery during the 5 years since their original operation. Of the patients with polyps, 20.6% had undergone revision compared to 15.5% of patients with CRS alone. The mean SNOT-22 score for all patients was 28.2 (standard deviation [SD] = 22.4) at 5 years after surgery. This is remarkably similar to the results observed at 3 months (25.5), 12 months (27.7), and 36 months (27.7), and represents a 14-point improvement over the baseline score. Polyp patients report better SNOT-22 scores at 5 years (mean = 26.2; SD = 21.6) than patients with CRS alone (mean = 33.3; SD = 23.7). Of the patients who had originally received simple polypectomy, 21.2% had undergone revision surgery compared to 20.0% of patients who had also received additional sinus surgery. The difference in unadjusted revision surgery rates is not statistically significant (chi(2) = 0.22; P = .64). However, the difference becomes statistically significant when a multivariate logistic regression is used to adjust for baseline characteristics, with patients undergoing additional sinus surgery being less likely to undergo further surgery within the study period (adjusted odds ratio = 0.66; P = .04).
We have shown sinonasal surgery to be safe and effective in reducing the symptoms associated with CRS over a 5-year period. The reduction in symptoms is large, with no significant decline in symptomatic improvement from 12 to 60 months postsurgery. However, revision surgery rates approach 20% over this time, and patients should be counseled accordingly prior to surgery.
目的/假设:我们报告了一项在英格兰和威尔士的医院中对接受慢性鼻-鼻窦炎(CRS)手术(伴或不伴鼻息肉)的患者进行的大型前瞻性队列研究。将报告 5 年的结果,并重新分析广泛手术治疗鼻息肉的效果。
为 3128 名接受 CRS 手术(伴或不伴鼻息肉)的患者收集了基线临床数据。根据接受再次手术的患者比例和 Sino-Nasal Outcome Test(SNOT-22)评分的平均值来描述结果。
共有 1459 名(52.2%)患者对 5 年随访做出了回应。每次随访时,再次手术的比率都在增加。在做出回应的患者中,279 名(19.1%)在原始手术后的 5 年内接受了进一步的手术。在有息肉的患者中,20.6%的患者进行了再次手术,而单独患有 CRS 的患者为 15.5%。所有患者在手术后 5 年的平均 SNOT-22 评分为 28.2(标准差[SD]=22.4)。这与术后 3 个月(25.5)、12 个月(27.7)和 36 个月(27.7)观察到的结果非常相似,比基线评分提高了 14 分。与单独患有 CRS 的患者(平均=33.3;SD=23.7)相比,患有鼻息肉的患者在 5 年后的 SNOT-22 评分更好(平均=26.2;SD=21.6)。在最初接受单纯息肉切除术的患者中,21.2%的患者接受了再次手术,而在接受鼻窦手术的患者中,20.0%的患者接受了再次手术。未调整的再次手术率没有统计学差异(卡方=0.22;P=0.64)。然而,当使用多元逻辑回归来调整基线特征时,差异具有统计学意义,接受鼻窦手术的患者在研究期间不太可能再次接受手术(调整后的优势比=0.66;P=0.04)。
我们已经证明,鼻-鼻窦手术在 5 年内安全且有效地减轻了与 CRS 相关的症状。症状的缓解幅度很大,从术后 12 个月到 60 个月,症状改善的幅度没有明显下降。然而,在此期间,再次手术的比率接近 20%,因此应在手术前对患者进行相应的咨询。